Justice S Ravinder Bhat of the Delhi High Court is a hero to some. His decision last month to allow generic drug manufacturer Cipla to continue manufacturing its version of Roche's patented lung cancer drug erlotinib (sold as Tarceva in India) has made him the toast of public health activists worldwide. Don't forget that this is the first case where a company in India, hub of generic manufacture, has brazenly broken a patent